55686-93-6

Basic information

• Product Name: 2-Chloro-7-methoxyquinoxaline
• Synonyms: 2-Chloro-7-methoxyquinoxaline
• CAS NO: 55686-93-6
• Molecular Formula: C₉H₇ClN₂O
• Molecular Weight: 194.62
• Mol File: 55686-93-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 102 °C
• Boiling Point: 297.3°C at 760 mmHg
• Flash Point: 133.6°C
• Appearance: /
• Density: 1.333g/cm³
• Vapor Pressure: 0.00241mmHg at 25°C
• Refractive Index: 1.628
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.61±0.30(Predicted)
• CAS DataBase Reference: 2-Chloro-7-methoxyquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-7-methoxyquinoxaline(55686-93-6)
• EPA Substance Registry System: 2-Chloro-7-methoxyquinoxaline(55686-93-6)

Safety Data

• Hazardous Substances Data: 55686-93-6(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 44, p. 1758, 2001 DOI: 10.1021/jm0005149

InChI:InChI=1/C9H7ClN2O/c1-13-6-2-3-7-8(4-6)12-9(10)5-11-7/h2-5H,1H3

Upstream product

• 55687-30-4 7-methoxyquinoxalin-2(1H)-one 
• 298-12-4 Glyoxilic acid 
• 102-51-2 4-methoxy-1,2-phenylenediamine 
• 924-44-7 glyoxylic acid ethyl ester 
• 59548-39-9 4-methoxyphenylene-1,2-diamine dihydrochloride 
• 55687-29-1 7-methoxy-3,4-dihydroquinoxalin-2(1H)-one 
• 55687-28-0 (4-methoxy-2-nitrophenyl)glycine 
• 96-96-8 4-methoxy-2-nitroaniline 
• 91192-32-4 6-methoxylquinoxalin-2(1H)-one 
• 91192-32-4 6-methoxyquinoxalin-2-ol 
• 55687-30-4 7-methoxyquinoxalin-2-ol 
• 31910-18-6 2,3-dihydroxy-6-methoxyquinoxaline 

Downstream Products

• 951240-20-3 7-methoxy-quinoxalin-2-ylamine 

Relevant articles and documents

Hepatitis C virus inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula wherein Ar, Het, R1 and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.